Cargando…
Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
In pre-clinical and clinical settings, active immunization with a Her-2/neu vaccine (HerVaxx), comprising B-cell peptide from Trastuzumab binding site, has been shown to reduce primary tumor growth via induction of polyclonal anti-tumor immune responses and immunological memory. Here, we tested the...
Autores principales: | Tobias, Joshua, Drinić, Mirjana, Högler, Sandra, Ambroz, Katharina, Baier, Karin, Kodajova, Petra, Tomasich, Erwin, Berghoff, Anna S., Schmid, Anna, Garner-Spitzer, Erika, Kenner, Lukas, Kundi, Michael, Zielinski, Christoph C., Wiedermann, Ursula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904231/ https://www.ncbi.nlm.nih.gov/pubmed/35259675 http://dx.doi.org/10.1016/j.tranon.2022.101378 |
Ejemplares similares
-
Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022) -
Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022) -
Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide
por: Tobias, Joshua, et al.
Publicado: (2017) -
HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006) -
Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)